Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics

Contributed by: PR Newswire

Tags

Frontier-GSK-RNA

More Like This

Novotech Report Reveals Growth in siRNA Research: Over 150 Industry-Sponsored Clinical Trials Conducted from 2020 to 2024

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

PR Newswire associated0

Skyhawk Therapeutics Announces Strategic Collaboration with Merck to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders

PR Newswire associated0

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates

PR Newswire associated0

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

PR Newswire associated0

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia